- Home
- SERV vs ESPR Comparison
SERV vs ESPR Comparison
Compare SERV & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- ESPR
- Stock Information
- Founded
- SERV 2017
- ESPR 2008
- Country
- SERV United States
- ESPR United States
- Employees
- SERV N/A
- ESPR N/A
- Industry
- SERV Industrial Specialties
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- ESPR Health Care
- Exchange
- SERV Nasdaq
- ESPR Nasdaq
- Market Cap
- SERV 338.7M
- ESPR 319.2M
- IPO Year
- SERV N/A
- ESPR 2013
- Fundamental
- Price
- SERV $8.00
- ESPR $2.12
- Analyst Decision
- SERV Strong Buy
- ESPR Buy
- Analyst Count
- SERV 3
- ESPR 4
- Target Price
- SERV $14.67
- ESPR $8.17
- AVG Volume (30 Days)
- SERV 6.4M
- ESPR 4.8M
- Earning Date
- SERV 11-07-2024
- ESPR 11-07-2024
- Dividend Yield
- SERV N/A
- ESPR N/A
- EPS Growth
- SERV N/A
- ESPR N/A
- EPS
- SERV N/A
- ESPR N/A
- Revenue
- SERV $1,679,360.00
- ESPR $295,451,000.00
- Revenue This Year
- SERV $901.23
- ESPR $198.22
- Revenue Next Year
- SERV $675.79
- ESPR $25.83
- P/E Ratio
- SERV N/A
- ESPR N/A
- Revenue Growth
- SERV 692.32
- ESPR 187.12
- 52 Week Low
- SERV $1.77
- ESPR $1.08
- 52 Week High
- SERV $30.00
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- ESPR 50.12
- Support Level
- SERV N/A
- ESPR $1.87
- Resistance Level
- SERV N/A
- ESPR $2.60
- Average True Range (ATR)
- SERV 0.00
- ESPR 0.17
- MACD
- SERV 0.00
- ESPR -0.01
- Stochastic Oscillator
- SERV 0.00
- ESPR 34.25
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an advanced, AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.